Sector News

Thermo Fisher to buy research contractor PPD in $17B deal

April 17, 2021
Life sciences

According to Daniel Arias, an analyst at Stifel, PPD is a “good strategic fit” for Thermo Fisher given the increasing demand for services provided by contract research organizations. Thermo Fisher, in announcing the acquisition, highlighted PPD’s drug development platform and strengths in laboratory services and patient recruitment.

Thermo Fisher expects the deal to immediately boost adjusted earnings per share, and estimates it will result in about $125 million worth of savings by the third year. PPD brought in $4.7 billion in revenue in 2020, and has more than 26,000 employees in 47 countries. Thermo Fisher, meanwhile had $32 billion in revenue last year and employs more than 80,000 people.

The announcement comes shortly after a failed attempt by Thermo Fisher to acquire molecular diagnostics company Qiagen. Thermo Fisher initially offered $11.5 billion for the company and then raised its bid, but was still unable to persuade Qiagen stockholders to tender their shares.

In a note to clients, Arias wrote that the integration of Patheon — a contract developer and manufacturer that Thermo Fisher bought for $7 billion in 2017 — should serve as a model for the latest acquisition. READ MORE

By Kristin Jensen

Source: biopharmadive.com

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend